Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer
NCT07126561Phase 2Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by University of Chicago. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07126561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126561.